ZA201702545B - Neuroactive compounds and methods of use thereof - Google Patents
Neuroactive compounds and methods of use thereofInfo
- Publication number
- ZA201702545B ZA201702545B ZA2017/02545A ZA201702545A ZA201702545B ZA 201702545 B ZA201702545 B ZA 201702545B ZA 2017/02545 A ZA2017/02545 A ZA 2017/02545A ZA 201702545 A ZA201702545 A ZA 201702545A ZA 201702545 B ZA201702545 B ZA 201702545B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- neuroactive compounds
- neuroactive
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201702545B true ZA201702545B (en) | 2019-06-26 |
Family
ID=55653736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/02545A ZA201702545B (en) | 2014-10-07 | 2017-04-10 | Neuroactive compounds and methods of use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20170304321A1 (enExample) |
| EP (1) | EP3204011A4 (enExample) |
| JP (3) | JP2017530982A (enExample) |
| KR (1) | KR20170065637A (enExample) |
| CN (2) | CN107405352A (enExample) |
| AU (2) | AU2015330906A1 (enExample) |
| BR (1) | BR112017007053A2 (enExample) |
| CA (1) | CA2963938C (enExample) |
| IL (2) | IL292465B2 (enExample) |
| MX (2) | MX388694B (enExample) |
| MY (1) | MY202135A (enExample) |
| PE (1) | PE20170907A1 (enExample) |
| PH (1) | PH12017500639A1 (enExample) |
| RU (1) | RU2764702C2 (enExample) |
| SG (2) | SG10202011773UA (enExample) |
| WO (1) | WO2016057713A1 (enExample) |
| ZA (1) | ZA201702545B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| IL298681A (en) * | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| DK3529257T3 (da) * | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN115103591B (zh) | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| WO2026102175A1 (en) * | 2024-11-06 | 2026-05-15 | Sage Therapeutics, LLC | Nmda receptor-modulatory compounds and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) * | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| WO2009137843A2 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| HUE062616T2 (hu) * | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| US20150119327A1 (en) * | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US9737522B2 (en) * | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| JP6419087B2 (ja) * | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| CN112057457A (zh) * | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| JP6628745B2 (ja) * | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3166613A4 (en) * | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
-
2015
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en not_active Withdrawn
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276946A (en) | Antiproliferative compounds and methods of use | |
| IL251505B (en) | Neuroactive compounds and methods of using them | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| IL313511A (en) | Compounds acting on glycans and methods of using them | |
| LT3089971T (lt) | Junginiai ir panaudojimo būdai | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| GB201418350D0 (en) | Dispenser and methods of use thereof | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| IL248529B (en) | Palladianolide pyridine compounds and methods of use | |
| IL253234A0 (en) | Methods for transdifferentiation and methods to use them | |
| ZA201606450B (en) | Compounds and their methods of use | |
| GB201403697D0 (en) | Compounds and methods of use | |
| HK1240856A1 (en) | Neuroactive compounds and methods of use thereof | |
| HK1228198A1 (en) | Compounds and their methods of use | |
| GB201416797D0 (en) | Contianer and method of use thereof | |
| GB201507707D0 (en) | Components and methods for formation of components |